# Senior Director, Team Lead, CDK4/6 Portfolio, US Breast Cancer — Pfizer

- Location: United States
- Posted pay: $231k–$385k/yr
- Posted: Nov 16, 2026
- Status: open (checked Nov 21, 2026)
- Apply (employer's site): https://pfizer.wd1.myworkdayjobs.com/PfizerCareers/job/United-States---New-York---New-York-City/Senior-Director--Team-Lead--CDK4-6-Portfolio--US-Breast-Cancer_4968031-1
- Employer record: https://visajobs.io/company/pfizer.md

## Sponsorship history
- Tier: Employer history only
- With this exact title: 0

## Description
ROLE SUMMARY
Pfizer Commercial Oncology is introducing the world to the next era of cancer care. With a growing portfolio of novel therapies, industry-leading R&D, and a goal of delivering eight breakthroughs by 2030 across major cancer types, we're translating cutting-edge science into market-shaping impact. Here, you'll partner with exceptional colleagues across scientific, medical, and manufacturing teams, backed by advanced digital and AI-enabled infrastructure and the authority to accelerate medicines from discovery to delivery. Guided by our values of courage, excellence, equity, and joy, you'll have the opportunity to stretch your skills and build a career that evolves with you—across teams, roles, and the Pfizer enterprise. Join us to make history — for patients, for their families, for the future.
Breast cancer is the most common cancer affecting women in the US, and IBRANCE, our first-in-class CDK 4/6 inhibitor, has been prescribed to ~200,000 patients in the US since launch. In 2026, IBRANCE contributed >$2B in net revenue to Pfizer Oncology and continues to be a market leader despite intensifying competition. With the June 2026 FDA approval of the PATINA HER2+ indication, IBRANCE is now the only CDK4/6 inhibitor indicated for HR+ metastatic breast cancer regardless of HER2 status.
The next three years are the most consequential in the history of Pfizer’s breast cancer business. IBRANCE faces IRA effectuation and LOE in 2027, and atirmociclib, our CDK4-selective inhibitor, is the portfolio’s planned successor. Phase 2 randomized results from the FOURLIGHT-1 study of atirmociclib, plus fulvestrant in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) who had received prior CDK 4/6 inhibitor-based treatment were presented at ESMO. These results further support atirmociclib as a potential first-in-class cell cycle inhibitor backbone for HR+, HER2- MBC and Pfizer’s development strategy in earlier lines of therapy. A Phase 3 study in frontline MBC is ongoing and an additional Phase 3 study in early breast cancer is planned to evaluate atirmociclib in combination with giredestrant, an investigational oral selective oestrogen receptor.
The same oncologists, accounts and treatment decisions are involved in both. This is a P&L and people-management leadership role that demands a strong enterprise leader. The colleague who leads this team will set a multi-year strategic vision, make thoughtful trade-off and resource prioritization decisions for both brands, and influence senior leadership across the wider organization. The role leads that transition as one integrated strategy: maximizing IBRANCE value through the PATINA launch/10 year heritage campaign, IRA and LOE while building the market, evidence and organization that atirmociclib will need.
The IBRANCE and atirmociclib commercial leader will pave the way internally and guide the cross functional team to innovate in all aspects of engagement across all stakeholder groups.
ROLE RESPONSIBILITIES
This Senior Director, Team Lead role reports to the VP, US Breast Cancer Franchise Lead and is an excellent opportunity for an experienced, collaborative and strategic leader to own the IBRANCE P&L and the atirmociclib pre-launch investment plan: own forecasting, OpEx and resource allocation, manage the revenue and expense trade-offs of LOE, and ensure every dollar released from IBRANCE is redeployed deliberately against portfolio priorities. The role leads a team of 6-8 HCP & patient marketers at the Director and Sr. Manager level. Atirmociclib is a critical launch for the Oncology portfolio over the next 5 years.
1. Optimize ~2B IBRANCE net revenue through 10 year heritage, IRA and LOE
Define and manage IBRANCE strategy and tactical execution through LOE, including identifying and executing incremental growth opportunities.
Lead the LOE plan: scenarios, customer and account communication, partnerships, patient marketing and generic-entry readiness, in partnership with Market Access, Trade, Legal and Medical.
Directly accountable for P&L Management and driving performance of marketing tactics and set investment levels against a clear profit-optimization framework, maximizing ROI through thoughtful trade-offs and redirecting savings to franchise priorities on an agreed timeline.
2. Build atirmociclib launch readiness & set a multi-year strategy
Launch excellence in frontline MBC and early breast cancer indications with a potential multibillion dollar revenue as a preferred next-generation backbone.
Set a multi-year strategic vision to anticipate the shifts in the HR+ve / HER2 -ve competitive landscape, evolving standards of care, and shape the brand strategy today to launch this multi-indication brand over the next 3 years.
Strategize proactively with Market Access, Pricing and Trade to shape the atirmociclib pricing and contracting strategy, channel and distribution model, and gross-to-net plan, ensuring the launch is positioned for durable access and profitability
Lead US HCP and account strategy for atirmociclib: positioning against generic CDK4/6 inhibitors, segmentation, target customers and the launch plan.
Shape the first-line market before approval with disease-state education and pre-launch engagement, in partnership with Medical Affairs and Clinical Development.
Define launch-readiness milestones, evidence needs and the investment case in partnership with Global, Market Access, Commercial Insights and Sales.
Continuously own the measurement and impact of marketing initiatives — using advanced analytics to generate learnings and drive continuous improvement against brand objectives.
Ensure marketing materials are compelling, compliant and appropriate across all channels, including AI-enabled and omnichannel touchpoints.
Identify strategic customer insights through collaboration with Medical, Market analytics, AI/data-science, field force a

> History, not a promise: past H-1B filings do not mean an employer will sponsor you or a given role. Data: U.S. DOL OFLC LCA disclosure (FY2024–FY2026 for role counts, certified LCAs) and the USCIS H-1B Employer Data Hub. Not legal advice. Methodology: https://visajobs.io/methodology
